CCS is a fast growing biotechnology division within the New York Blood Center, that provides an unaffiliated, neutral platform for a wide range of clinical trial needs in the areas of regenerative medicine, cell therapies, transfusion medicine, and related endeavors.
For clinical grade production of ExCellThera’s lead cell therapy product, ECT-001 technology
NY1 News goes inside NYBC headquarters, where scientists carry out an important mission: researching treatments for diseases that affect blood.
Through NYBC, Comprehensive Cell Solutions is able to provide a number of blood products from healthy blood donors for research use
A Conceptual Overview of the Cellular Therapy Supply Chain Pathway
Cellular therapy products are increasingly manufactured using cGMP regulations in clean room facilities and creating a cGMP facility from scratch can be an expensive and time consuming endeavor.
Follow our blog for the latest news and insights from our experts to stay at the forefront of the industry.
Comprehensive Cell Solutions™ (CCS) leverages NYBC's strengths of innovation, flexibility, mobility, creativity, and quality.
At every step in the pipeline.
Stay at the forefront of the industry.
Don't see what you're looking for? Please ask!